Detail Data
Volume (24h): 1,209,308 shares
P/E Ratio: /
Forward P/E: -12.22
EPS: -4.07 USD
Forward EPS: -1.22 USD
Number of Shares: 88,771,696 shares
Market Capitalization: 1,323,585,920.00 USD

Dividend

Dividend Value
Dividend Amount According to our data, the company Travere Therapeutics does not currently pay dividends.
Annual Yield %: -
Ex-dividend Date: -
5-Year Avg Yield %: -
Payout Ratio: -
Last Dividend Value: -
Last Dividend Date: -

Analyst Forecast

Most analysts have issued a strong_buy recommendation for Travere Therapeutics stock. The current number of analysts covering this company is 15. The highest target price is 47 USD, while the lowest target price is 22 USD. The median target valuation set by analysts is 30 USD. These forecasts and recommendations provide insight into how analysts view the future stock performance of Travere Therapeutics.
Analysts Recommendation
Issued Recommendation: According to our data, the recommendation for Travere Therapeutics stock is: strong_buy
Number of Analysts: 15
Highest Target Price: 47 USD
Lowest Target Price: 22 USD
Median Target Price: 30 USD

Fundamental Indicators

Indicator Data
Total Revenue: 233,175,008.00 USD
Net Income: -320,630,016.00 USD
Price-to-Book (P/B): 22.06
PEG Ratio: /
Exchange: NasdaqGM
Industry: Biotechnology
Sector: Healthcare
Number of Employees: 385
Country: United States

Where to Buy Travere Therapeutics Stock?

You can purchase Travere Therapeutics stock on the NasdaqGM under the ticker symbol: TVTX. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.

1

Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.

Trustpilot rating 4.4/5 Google play rating 4.2/5
Invest in Stocks with eToro
★★★★★ 5.0
2

Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.

Trustpilot rating 3.6/5 Google play rating 4.5/5
Try Free Demo Account
★★★★☆ 4.8
Risk warning: Trading CFDs involves a high risk of financial loss. Between 51%-eToro -89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

More Information on Travere Therapeutics Stock

Indicator Value
Company Revenue: 233,175,008.00 USD
EBITDA: -212,628,992.00 USD - Negative EBITDA may signal financial challenges or growth investments.
Earnings Per Share: -4.07 USD
Book Value Per Share: 0.68 USD
Total Cash: 370,700,992.00 USD
Total Cash per Share: 4.18 USD
Total Debt: 401,584,000.00 USD
Debt to Equity Ratio: 6.80
Quick Ratio 1.99
Current Ratio 2.08
Free Cash Flow -228,530,752.00 USD
Operating Cash Flow -237,475,008.00 USD
Gross Margins 3.40 %
EBITDA Margins -91.19 %
Operating Margins -79.34 %
Profit Margins -137.90 %
Return on Assets -23.2 %
Return on Equity -246.7 %
Earnings Growth (1 year) -
Revenue Growth (1 year) 66.0 %
Quarterly Earnings Year-over-Year Growth -
Market Capitalization 1,323,585,920.00 USD
Enterprise Value 1,353,993,856.00 USD
EV/Revenue 5.807
EV/EBITDA -6.368
Float Shares 75,684,423 shares
Shares Outstanding 88,771,696 shares
Held Percent Insiders 0.01 %
Held Percent Institutions 109.28 %
Shares Short 11,556,812
Shares Short Prior Month 10,948,550
Date Short Interest 2025-03-31
Short Percentage of Total Shares 13.02 %
Short Ratio 7.05
Beta 0.84
Short Percentage of Float 13.11 %
Implied Shares Outstanding 88,771,696

Frequently Asked Questions (FAQ)

According to our data, the company Travere Therapeutics does not pay dividends yet, even in 2025.

Travere Therapeutics shares are traded on the NasdaqGM stock exchange under the ticker: TVTX. You can buy or trade them through a variety of stock brokers who provide real stock trading services.

According to our data, the recommendation for Travere Therapeutics shares is from a total of 15 analysts. The average target price prediction is 30 USD per share.

The total number of Travere Therapeutics shares on the exchange is 88,771,696.00 shares, which at the current market capitalization gives the company a total valuation of 1,323,585,920.00 USD.